National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Evolocumab (Repatha®)

Evolocumab (Repatha®) is indicated for both primary hypercholesterolaemia and mixed dyslipidaemia and heterozygous familial hypercholesterolaemia.


NCPE Assessment Process Complete
NCPE assessment process completed 2016 October 2016
NCPE assessment outcome 2016 Reimbursement not recommended

Summary 2016

NCPE Assessment Process Complete
Full pharmacoeconomic assessment recommissioned by HSE 31/05/2017
Pre-submission consultation with applicant 27/06/2017
Submission received from applicant 31/10/2017
Preliminary review sent to applicant 20/11/2017
NCPE assessment re-commenced 02/01/2018
Preliminary review 2 sent to applicant 26/01/2018
NCPE assessment re-commenced 29/03/2018
Factual accuracy sent to applicant 13/04/2018
NCPE assessment re-commenced 30/04/2018
NCPE assessment completed 16/05/2018
Full pharmacoeconomic assessment outcome The NCPE recommends that evolocumab should not be reimbursed unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.


The HSE has approved reimbursement following confidential price negotiations; anticipated reimbursement date July 2019